• Connect With Us
Clinical Research

Active In-House Studies at Virginia Hospital Center

Investigator: Walter L. Atiga, M.D.

Mentor Protocol Title: ENSURE Cardiac Resynchronization Therapy Study.

Investigator: Walter L. Atiga, M.D.

Guidant Protocol Title: REFLEX Study: ENDOTAK RELIANCE G Evaluation of Handling and Electrical Performance.

Investigator: John R. Garrett, M.D.

Protocol Number: Nabi Biopharmaceuticals Protocol Nabi-1366.
Protocol Title: A multicenter, randomized, placebo-controlled, double-blinded study to evaluate safety and immunogenicity of StaphVAX, a bivalent staphylococcus aureus glycoconjugate vaccine in adult patients undergoing cardiovascular surgery.

Investigator: John R. Garrett, M.D.

Protocol Number: Alexion and Proctor & Gamble Protocol 2003141
Protocol Title: A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of 2 mg/kg bolus plus 24-hour 0.5 mg/kg/hr infusion pexelizumab in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass.

Investigator: Ramanath Gopalan, M.D. 

Protocol Number: Eli Lilly Protocol F1D-US-HGLS.
Protocol Title: Olanzipineversus Aripiprazole in the treatment of acutely ill patients with schizophrenia.

Investigator: Michael P. Notarianni, M.D.

Protocol Number: AstraZeneca Protocol 4522US/0001
Protocol Title: A 12-week, randomized, open-label, 3-arm, parallel group, multicenter, phase IIIb study comparing the efficacy and safety of Rosuvastatin 20mg and 40mg with that of Atorvastatin 80mg in subjects with acute coronary syndromes [LUNAR].

Investigator: Talal A. Munasifi, M.D.

Protocol Number: WIRB 96564
Protocol Title: Adjunct study for Mentor H/S silicone gel-filled mammary prosthesis.

Investigator: Dr. Tariq Shahab, M.D.

Protocol Number: WIRB 1585
Protocol Title: Safety and efficacy of Jomed Jostent coronary stent-graft in the treatment of free perforations during percutaneous coronary interventions.

Investigator:  Ramanath Gopalan, M.D.

Protocol Number:   Pfizer A1281110
Protocol Title:   A Four-Week Double-Blind Multi-Center Study Comparing the Efficacy and Safety of Ziprasidone to Aripiprazole in Subjects with Scizophrenia or Schizoaffective Disorder Needing Inpatient Care

Investigator:  Steven K. Neufeld, M.D.

Protocol Number:  1
Protocol Title:  The Foot and Ankle Post-op Pain Trial (the FA-POP trial):  A Patient Oriented Study

Investigator:  Ramanath Gopalan, M.D.

Protocol Number:  Pfizer and Organon A7501005
Protocol Title:  A Phase III, Randomized, Placebo-Controlled, Double-Blind Trial Evaluating the Safety and Efficacy of Sublingual Azenapine vs. Olanzapine and Placebo in In-Patients with an Acute Manic Episode.

Investigator:  Ramanath Gopalan, M.D.

Protocol Number: Pfizer and Organon A7501006
Protocol Title:  A Double-Blind, 9-Week Extension Study Evaluating the Safety and Maintenance of Effect of Azenapine vs. Olanzapine in the Treatment of Subjects with Acute Mania.

Investigator:  Ramanath Gopalan, M.D.

Protocol Number:  Solvay S1543004
Protocol Title: A Randomized, Double-Blind, Olanzapine-Referenced, Parallel-Group Safety and Efficacy Study of Flexible Doses of Bifeprunox in the Long-Term Treatment of Schizophrenia (Extension of Protocol S1543003)

Investigator:  Rita Wong, EdD., PT

Protocol Title:  Barriers and Facilitators to the Diffusion of a Comprehensive Balance and Falls Prevention Program within a Hospital.

Investigator:Ramanath Gopalan, M.D.

Protocol Number: Pfizer and Organon 041023
Protocol Title:AMulticenter, Randomized, Double-Blind, Fixed -Dose, 6-Week Trial of Efficacy and Safety of Asenapine Compared with Placebo Using Haloperidol Positive Control in Subjects with an Acute Exacerbation of Schizophrenia

Investigator:Ramanath Gopalan, M.D.

Number: Pfizer and Organon 04513
Protocol Title: A Multicenter, Double-Blind, Flexible-Dose, Long-Term Extension Trial 6-Week Trial of the Safety and Maintenance of Effect of Asenapine Using Haloperidol Positive Control in Subjects  Who Complete Protocol 041023

Investigator:  Walter Atiga

Title:  Medtronic Partners HF
Multi-Site Program to Access and Review Trending Information and Evaluate CoR Relation to Symptoms in Patients with Heart Failure

Investigator:  Charanjit S. Khurana, M.D.

Number:  Pfizer A7641006
Title: A Phase 2 Double-Blind, Placebo-Controlled, Parallel-Group, Dose Ranging Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ET-00216 in Patients with Acute Coronary Syndromes

Investigator:  David Duhamel, M.D.

Number Asthmatx 04-02
Protocol Title: Safety and Effectiveness of the Alair System for the Treatment of Asthma:  A Muticenter Randomized Clinical Trial (Asthma Intervention Research (AIR2) Trial)

Investigator:  Ramanath Gopalan, M.D.

Number: GlaxoSmithKline NAA104606
Protocol Title: A Multicenter, Double-Blind, Double Dummy, Placebo-Controlled, Randomized, Adaptive, Dose-Range Study to Evaluate the Safety and Efficacy of SB-773812 Administered Once daily for 12 Weeks in Adults with Schizophrenia"

Share:
Find a Doctor
Search
Contact Info

1701 N. George Mason Drive | Arlington, VA 22205-3698 | tel 703.558.5000
© 2014 Virginia Hospital Center All rights reserved